Suppr超能文献

热带真菌病的治疗。

Treatment of tropical mycoses.

作者信息

Restrepo A

机构信息

Mycology Section, Corporacion para Investigaciones Biologicas, Hospital Pablo Tobon Uribe, Medellin, Colombia, South America.

出版信息

J Am Acad Dermatol. 1994 Sep;31(3 Pt 2):S91-102. doi: 10.1016/s0190-9622(08)81277-7.

Abstract

Several subcutaneous and deep-seated mycoses are either observed more frequently in the tropical areas or are restricted to certain regions within the tropics. These mycoses include sporotichosis, chromoblastomycosis, entomophthoromycosis, eumycetoma, lobomycosis, and paracoccidioidomycosis. In sporotrichosis and paracoccidioidomycosis, therapy often results in either complete resolution or marked improvement. For decades sporotrichosis has been treated successfully with potassium iodide, but recently the triazole compounds, especially itraconazole, have proved effective and free of major side effects. The usual therapy for paracoccidioidomycosis is sulfonamides or amphotericin B; the former requires prolonged treatment, whereas the latter causes a significant degree of toxicity. Various azole derivatives (ketoconazole, fluconazole, saperconazole, and itraconazole) allow shorter treatment courses, can be given orally, and are more effective. Presently, itraconazole is the drug of choice. Chromoblastomycosis is a difficult condition to treat, especially if it is caused by Fonsecaea pedrosoi. Several therapeutic approaches have been used, including heat, surgery, cryotherapy, thiabendazole, amphotericin B combined with flucytosine, and azole derivatives, but their success has been modest. A 65% response rate has been obtained with itraconazole given for periods of 6 to 19 months; in limited trials, saperconazole appears to be more effective and requires shorter treatment courses. Only a few patients with eumycetoma respond to therapy; 70% of patients with Madurella mycetomatis respond to prolonged treatment with ketoconazole. Griseofulvin has been tried in nonresponders with partial success. Limited data in patients with Fusarium species eumycetoma indicate good responses to itraconazole. Eumycetoma caused by Pseudallescheria boydii or Acremonium species has been refractory to therapy. Therapy of entomophthoromycosis is also difficult because the diagnosis is usually established late and not all patients respond to therapy; this situation applies to infection caused by either Basidiobolus haptosporus or Conidiobolus coronatus. Although there is no consensus, African physicians prefer to use potassium iodide or trimethoprim-sulfamethoxazole. Isolated reports indicate that the azole derivatives, including the triazoles, may be effective. As for lobomycosis, all attempts at medical treatment have failed. Surgery is successful only when the lesion is small and can be fully resected; repeated cryotherapy appears to be more successful.

摘要

几种皮下和深部真菌病要么在热带地区更频繁地被观察到,要么局限于热带地区的某些区域。这些真菌病包括孢子丝菌病、着色芽生菌病、虫霉病、真菌性足菌肿、洛博芽生菌病和副球孢子菌病。在孢子丝菌病和副球孢子菌病中,治疗通常会导致完全缓解或显著改善。几十年来,碘化钾成功地用于治疗孢子丝菌病,但最近三唑类化合物,尤其是伊曲康唑,已被证明有效且副作用小。副球孢子菌病的常用治疗方法是磺胺类药物或两性霉素B;前者需要长期治疗,而后者会引起相当程度的毒性。各种唑类衍生物(酮康唑、氟康唑、沙康唑和伊曲康唑)疗程较短,可以口服,且更有效。目前,伊曲康唑是首选药物。着色芽生菌病是一种难以治疗的疾病,尤其是由裴氏着色霉引起的。已经使用了几种治疗方法,包括热疗、手术、冷冻疗法、噻苯达唑、两性霉素B联合氟胞嘧啶以及唑类衍生物,但效果并不理想。给予伊曲康唑6至19个月可获得65%的缓解率;在有限的试验中,沙康唑似乎更有效且疗程较短。只有少数真菌性足菌肿患者对治疗有反应;70%的马杜拉足菌肿患者对酮康唑长期治疗有反应。对无反应者试用灰黄霉素取得了部分成功。关于镰刀菌属真菌性足菌肿患者的有限数据表明对伊曲康唑反应良好。由波氏假阿利什霉或枝顶孢属引起的真菌性足菌肿对治疗难治。虫霉病的治疗也很困难,因为诊断通常较晚确立,而且并非所有患者对治疗都有反应;这种情况适用于由哈氏担子菌或冠状耳霉引起的感染。尽管尚无共识,但非洲医生更倾向于使用碘化钾或甲氧苄啶-磺胺甲恶唑。个别报告表明,包括三唑类在内的唑类衍生物可能有效。至于洛博芽生菌病,所有药物治疗尝试均失败。只有当病变较小且能完全切除时,手术才会成功;反复冷冻疗法似乎更成功。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验